IVI RMA New Jersey, Basking Ridge, NJ.
Department of Obstetrics and Gynecology, Bridgeport Hospital, Bridgeport, CT.
Am J Obstet Gynecol MFM. 2020 Nov;2(4):100232. doi: 10.1016/j.ajogmf.2020.100232. Epub 2020 Sep 22.
The positive predictive value of noninvasive prenatal testing is approximately 69% in the general population. However, positive predictive value is dependent on the prevalence of the disease in the population being tested. Patients who undergo in vitro fertilization with preimplantation genetic testing for aneuploidy and transfer a euploid embryo are presumably a lower risk population than the general population.
In this study, we explored the positive predictive value of noninvasive prenatal testing in women undergoing in vitro fertilization with preimplantation genetic testing for aneuploidy and subsequent transfer of a euploid embryo.
This study was a retrospective cohort study. All patients who underwent in vitro fertilization with preimplantation genetic testing for aneuploidy followed by transfer of a single euploid embryo between 2014 and 2019 at a university-affiliated fertility center were contacted. Noninvasive prenatal testing results were reviewed and those with positive noninvasive prenatal testing were identified. Results of any subsequent prenatal or postnatal diagnostic testing were used to classify each positive noninvasive prenatal testing as a true positive or a false positive. The prevalence and positive predictive value of positive noninvasive prenatal testing was calculated.
A total of 1139 patients that underwent noninvasive prenatal testing after transfer of a euploid embryo were identified, 8 of which had positive noninvasive prenatal testing screens. Although 6 of these patients had subsequent definitive prenatal diagnostic testing that revealed a euploid karyotype concordant with their preimplantation genetic testing for aneuploidy results, 1 patient opted out of diagnostic testing and later delivered a normal baby. Of note, 1 patient who had noninvasive prenatal testing positive for Turner syndrome underwent amniocentesis, which confirmed Turner mosaicism (45,X karyotype in 80% of cells). Therefore, the positive predictive value of noninvasive prenatal testing in this patient cohort was 12.5%.
Clinicians and patients should recognize that patients undergoing transfer of a euploid embryo are at a relatively lower risk for fetal aneuploidy than the general population, and the positive predictive value of noninvasive prenatal testing is lower in this setting.
非侵入性产前检测的阳性预测值在一般人群中约为 69%。然而,阳性预测值取决于所检测人群中疾病的流行率。接受体外受精并进行胚胎植入前非整倍体检测且移植整倍体胚胎的患者,其风险比一般人群低。
本研究旨在探讨体外受精并进行胚胎植入前非整倍体检测且移植整倍体胚胎的女性中,非侵入性产前检测的阳性预测值。
这是一项回顾性队列研究。联系了 2014 年至 2019 年在一家大学附属生育中心接受体外受精并进行胚胎植入前非整倍体检测且随后移植单个整倍体胚胎的所有患者。回顾了非侵入性产前检测结果,并确定了阳性非侵入性产前检测结果。随后使用任何产前或产后诊断检测的结果将每个阳性非侵入性产前检测结果分类为真阳性或假阳性。计算了阳性非侵入性产前检测的患病率和阳性预测值。
共确定了 1139 例接受整倍体胚胎移植后的非侵入性产前检测患者,其中 8 例非侵入性产前检测结果阳性。尽管其中 6 例患者随后进行了明确的产前诊断检测,结果显示与胚胎植入前非整倍体检测结果一致的整倍体核型,但 1 例患者选择不进行诊断检测,随后分娩了正常婴儿。值得注意的是,1 例非侵入性产前检测结果阳性特纳综合征的患者接受了羊膜穿刺术,证实为特纳嵌合体(80%的细胞为 45,X 核型)。因此,在该患者队列中,非侵入性产前检测的阳性预测值为 12.5%。
临床医生和患者应认识到,接受整倍体胚胎移植的患者胎儿非整倍体的风险比一般人群相对较低,并且在这种情况下,非侵入性产前检测的阳性预测值较低。